Abstracts tagged "Abatacept"

Abstract Number: 2774 • 2015 ACR/ARHP Annual Meeting
Longterm Outcome of Patients Switched from Iv to Sc Formulation of Abatacept: A Monocentric Study
Rossella Reggia¹, Ilaria Cavazzana¹, Angela Tincani² and Franco Franceschini¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose: Abatacept is a selective T cell costimulation modulator indicated for active Rheumatoid Arthritis (RA). Since August 2013, in Italy, the drug has also been…
Abstract Number: 563 • 2015 ACR/ARHP Annual Meeting
Abatacept Plus Methotrexate Can Effectively and Safely Regain the Target of Remission Following Re-Treatment for Flares after Drug-Free Withdrawal in Patients with Early Rheumatoid Arthritis
Paul Emery¹, G Burmester², VP Bykerk³, B Combe⁴, Daniel E. Furst⁵, M Maldonado⁶ and T. W. J. Huizinga⁷, ¹University of Leeds, Leeds, United Kingdom, ²Charité – University Medicine Berlin, Berlin, Germany, ³Hospital for Special Surgery, New York, NY, ⁴Service d’Immuno-Rheumatologie, Montpellier, France, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Assessing Very Early Rheumatoid arthritis Treatment (AVERT) was a Phase IIIb, randomized, active-controlled study to evaluate the efficacy and safety of abatacept (ABA) treatment…
Abstract Number: 584 • 2015 ACR/ARHP Annual Meeting
Positivity for Rheumatoid Factor Is Associated with a Better Short-Term Response and Long-Term Drug Retention of Abatacept: Results from Consecutive 508 Patients with Rheumatoid Arthritis in a Japanese Multicenter Registry
Nobunori Takahashi¹, Toshihisa Kojima¹, Koji Funahashi² and Naoki Ishiguro³, ¹Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ²Nagoya University Hospital, Nagoya, Japan, ³Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Abatacept (ABT) is a biologic drug and has been available for rheumatoid arthritis (RA) patients since 2010 in Japan. There have still been few…
Abstract Number: 592 • 2015 ACR/ARHP Annual Meeting
The Impact of Tobacco Smoking on the Effectiveness of Abatacept in Rheumatoid Arthritis: Data from a Paneuropean Analysis of RA Registries
Axel Finckh^1,2, Jacques Gottenberg³, M. Victoria Hernández⁴, Florenzo Iannone⁵, Elisabeth Lie⁶, Helena Canhao⁷, Karel Pavelka⁸, Carl Turesson⁹, Merete Lund Hetland¹⁰ and Xavier Mariette¹¹, ¹Rheumatology Division, University Hospital of Geneva, Geneva, Switzerland, ²Div of Rheumatology, University of Geneva, Geneva, Switzerland, ³Hautepierre, Strasbourg, France, ⁴Arthritis Unit, Rheumatology, Hospital Clinic, Barcelona, Spain, ⁵Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy, ⁶Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁷Rheumatology Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal, ⁸Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁹Lund University, Rheumatology, Dept. of Clinical Sciences,, Malmö, Sweden, ¹⁰Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ¹¹Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France
Background/Purpose: It has previously been shown that current smoking is a predictor of poor response to methotrexate or anti-TNF treatment in rheumatoid arthritis (RA). The…
Abstract Number: 608 • 2015 ACR/ARHP Annual Meeting
Safety of Surgery in Patients with Rheumatoid Arthritis Treated By Abatacept: Data from the French Orencia in Rheumatoid Arthritis (ORA) Registry
Augustin Latourte¹, Jacques Gottenberg², Cécile Luxembourger³, Isabelle Pane⁴, Pascal Claudepierre⁵, Pascal Richette¹, Pierre Lafforgue⁶, Philippe Ravaud⁴, BG Combe⁷, Alain G. Cantagrel³, Jean Sibilia⁸, Rene-Marc Flipo⁹, Philippe Gaudin¹⁰, Olivier Vittecoq¹¹, Thierry Schaeverbeke¹², Maxime Dougados¹³, Francis Berenbaum¹⁴, Jérémie Sellam¹⁵, Xavier Mariette¹⁶ and Raphaèle Seror¹⁷, ¹Fédération de Rhumatologie, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ²Rheumatology, Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ³Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, ⁴Centre de Recherche en Epidémiologie et Statistiques, INSERM U1153, Centre d'Épidémiologie Clinique, Hôpital Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris (AP-HP), Descartes University, Paris, France, ⁵Rheumatology, Université Paris Est Créteil, Créteil, France, ⁶Rheumatology, APHM, Aix Marseille University, Marseille, France, ⁷Rhumatologie, Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ⁸Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁹Rheumatology, Hopital R Salengro CHRU, Lille, France, ¹⁰Department of Rheumatology, University Hospital Grenoble, Grenoble, France, ¹¹University Hospital, Rouen, France, ¹²Rheumatology Department, Bordeaux Hospital, Bordeaux, France, ¹³Medicine Faculty, Paris-Descartes University, Paris, UPRES-EA 4058, Cochin Hospital, Rheumatology B, Paris, France, ¹⁴Rheumatology, Inserm UMRS_938, AP-HP, St Antoine Hospital, Univ Paris 06, DHU i2B, Paris, France, ¹⁵Rheumatology and Inserm UMRS_938, AP-HP, St Antoine Hospital, Univ Paris 06, DHU i2B, Paris, France, ¹⁶Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ¹⁷Rheumatology, AP-HP Bicêtre Hospital / Paris-Sud University, Le Kremlin-Bicêtre, France
Background/Purpose: The aim of this study was to investigate the frequency and risk factors of postoperative complications in rheumatoid arthritis (RA) patients treated with abatacept…
Abstract Number: 1310 • 2015 ACR/ARHP Annual Meeting
Efficacy of Abatacept in Patients with Rheumatoid Arthritis Assessed By MRI Scans of Bilateral Hands
Yuji Kukida¹, Akiko Kasahara¹, Takahiro Seno^1,2, Yu Isoda¹, Tomoya Sagawa¹, Takuya Inoue¹, Naoka Kamio¹, Risa Sagawa¹, Takashi Kida¹, Amane Nakabayashi¹, Hidetake Nagahara³, Ken Murakami¹, Aihiro Yamamoto¹, Satoshi Morita⁴, Hirotoshi Ito⁵, Masataka Kohno¹ and Yutaka Kawahito¹, ¹Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ²Department of Rheumatic Diseases and Joint Function, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ³Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ⁴Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁵Department of Radiology, Kajiicho Medical Imaging Center, Kyoto, Japan
Background/Purpose: Previous radiographic and MRI studies have demonstrated that abatacept (ABT) can inhibit the progression of bone and joint destruction in patients with rheumatoid arthritis…
Abstract Number: 1524 • 2015 ACR/ARHP Annual Meeting
Evaluation of Changes in Cardiovascular Risk Factors Among Patients with RA Prescribed Biologic Dmards
E Alemao¹, T Simon², KK Gandhi¹, H Kawabata² and Jeffrey R. Curtis³, ¹Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Hopewell, NJ, ³University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Studies have reported that TNF-inhibitors (TNF-Is) are associated with a reduced risk of cardiovascular (CV) events,1 but data on their effects on traditional CV…
Abstract Number: 1840 • 2014 ACR/ARHP Annual Meeting
Pregnancy Outcomes Following Exposure to Abatacept during Pregnancy
M Kumar¹, L Ray¹, S Vemuri² and T Simon¹, ¹Bristol-Myers Squibb, Hopewell, NJ, ²Bristol-Myers Squibb, Plainsboro, NJ
Background/Purpose: Limited data are currently available in the medical literature to guide counseling of patients regarding pregnancy outcomes when treated with abatacept, a selective T-cell…
Abstract Number: 132 • 2014 ACR/ARHP Annual Meeting
Do Ultrasound (PDUS) and DAS28 Measure Different Aspects of Disease Activity? Analyses from the First Prospective International Phase IIIb Study of PDUS Response in Abatacept-Treated Patients with Rheumatoid Arthritis (RA)
Maria-Antonietta d'Agostino¹, M Boers², R Wakefield³, H Berner Hammer⁴, O Vittecoq⁵, M Galeazzi⁶, P Balint⁷, I Möller⁸, A Iagnocco⁹, E Naredo^10,11, M Ostergaard¹², C Gaillez¹³, E Barre¹⁴, M Le Bars¹⁵ and On behalf of the OMERACT-EULAR-Ultrasound Task Force, ¹AP-HP Ambroise Paré Hospital, Boulogne-Billancourt, France, ²VU University Medical Center, Amsterdam, Netherlands, ³University of Leeds, Leeds, United Kingdom, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵University Hospital, Rouen, France, ⁶University of Siena, Siena, Italy, ⁷Rheumatology, National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ⁸Instituto Poal, Barcelona, Spain, ⁹Sapienza Università di Roma, Roma, Italy, ¹⁰Hospital Universitario Severo Ochoa, Madrid, Spain, ¹¹Hospital GU Gregorio Marañón, Madrid, Spain, ¹²Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ¹³Formerly of Bristol-Myers Squibb, Rueil-Malmaison, France, ¹⁴Bristol-Myers Squibb, Braine-L’Alleud, Belgium, ¹⁵Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: A composite (power Doppler/grayscale ultrasound [PDUS]) synovitis score, developed by the OMERACT-EULAR-Ultrasound Task Force, was shown to be responsive in RA patients with inadequate…
Abstract Number: 1578 • 2014 ACR/ARHP Annual Meeting
Abatacept Improves Synovitis As Assessed By Magnetic Resonance Imaging (MRI) in Psoriatic Arthritis – Preliminary Analysis from a Single Centre, Placebo-Controlled, Crossover Study
Agnes Szentpetery¹, Eric J. Heffernan², Muhammad Haroon³, Phil Gallagher¹, Anne-Marie Baker¹, Martina Cooney¹ and Oliver FitzGerald¹, ¹Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ²Radiology, St. Vincent's University Hospital, Dublin, Ireland, ³Newmarket On Fergus, Cork University Hospital, Cork, Ireland
Background/Purpose Abatacept is a soluble, fully human fusion protein which selectively inhibits T-cell activation via the CD80/CD86:CD28 co-stimulation pathway and decreases serum levels of inflammatory…
Abstract Number: 1532 • 2014 ACR/ARHP Annual Meeting
Efficacy of the Subcutaneous Formulation of Abatacept/Orencia in Rheumatoid Arthritis, a Single-Center Italian Experience
Rossella Reggia¹, Franco Franceschini¹, Angela Tincani² and Ilaria Cavazzana¹, ¹AO Spedali Civili, Rheumatology and Clinical Immunology Unit, Brescia, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose Abatacept is a selective T cell costimulation modulator indicated for moderately to severely active Rheumatoid Arthritis (RA). Since August 2013 is available in Italy…
Abstract Number: 1536 • 2014 ACR/ARHP Annual Meeting
Comparing Abatacept to Adalimumab, Etanercept and Infliximab As First Line Agents in Patients with Rheumatoid Arthritis. Experience from the Rhumadata® Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Isabelle Fortin³, Boulos Haraoui¹, Jean Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard⁴, Diane Sauvageau¹, Edith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁴Rhumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada
Background/Purpose: The order of use of biologic agents is still a question for debate. Phase III trial data in MTX-IR patients show comparable efficacy results…
Abstract Number: 1515 • 2014 ACR/ARHP Annual Meeting
The Impact on Anti-Citrullinated Protein Antibody Isotypes and Epitope Fine Specificity in Patients with Early RA Treated with Abatacept and Methotrexate
T W J Huizinga¹, S E Connolly², Daniel E. Furst³, Vivian P. Bykerk⁴, Gerd Burmester⁵, B G Combe⁶, C S Karyekar², D Wong², L Trouw¹, R E M Toes⁷ and P Emery⁸, ¹Leiden University Medical Center, Leiden, Netherlands, ²Bristol-Myers Squibb, Princeton, NJ, ³University of California at Los Angeles, Los Angeles, CA, ⁴Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁵Charité – University Medicine Berlin, Berlin, Germany, ⁶Montpellier University Hospital, Montpellier, France, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸University of Leeds, Leeds, United Kingdom
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are a marker of RA and may contribute to disease progression.1,2 ACPA analysis in patients offers the opportunity to estimate…
Abstract Number: 1520 • 2014 ACR/ARHP Annual Meeting
Gene Expression Analyses of Abatacept- and Adalimumab-Treated Patients from the Ample Trial
S Bandyopadhyay¹, M Maldonado¹, M Schiff², ME Weinblatt³, Roy Fleischmann⁴ and SE Connolly¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²University of Colorado, Denver, CO, ³Brigham and Women's Hospital, Boston, MA, ⁴University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The distinct mechanisms of action (MoA) of abatacept (ABA) and adalimumab (ADA) are expected to manifest in different transcriptional profiles in RA patients (pts).…
Abstract Number: 1152 • 2014 ACR/ARHP Annual Meeting
Euroqol-5-Dimensions Utility Gain in Rheumatoid Arthritis, Treated with Abatacept, Rituximab, Tocilizumab or Tumor Necrosis Factor Inhibitors
Anders Gülfe¹, Johan A. Karlsson² and Lars-Erik Kristensen³, ¹Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden, ²Dept of Clinical Sciences, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden, ³Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Malmö, Sweden
Background/Purpose: We have earlier demonstrated that EuroQoL-5-Dimensions (EQ-5D) utility improves rapidly after commencement of tumor necrosis factor inhibition (TNFi) in rheumatoid arthritis (RA) and other…

« Previous Page
1
…
6
7
8
9
10
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].